Jes Olesen1, M.G. Bousser, H-C Diener, David W. Dodick, Michael B. First, Peter J. Goadsby, Hartmut Göbel, MJA Lainez, James W. Lance, Richard B. Lipton, Giuseppe Nappi2, Fumihiko Sakai, Jean Schoenen3, Stephen D. Silberstein, Timothy J. Steiner
1University of Copenhagen
2Fondazione Istituto Neurologico Casimiro Mondino
3Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie >
Tóm tắt
After the introduction of chronic migraine and medication overuse headache as diagnostic entities in The International Classification of Headache Disorders, Second Edition, ICHD-2, it has been shown that very few patients fit into the diagnostic criteria for chronic migraine (CM). The system of being able to use CM and the medication overuse headache (MOH) diagnosis only after discontinuation of overuse has proven highly unpractical and new data have suggested a much more liberal use of these diagnoses. The International Headache Classification Committee has, therefore, worked out the more inclusive criteria for CM and MOH presented in this paper. These criteria are included in the appendix of ICHD-2 and are meant primarily for further scientific evaluation but may be used already now for inclusion into drug trials, etc. It is now recommended that the MOH diagnosis should no longer request improvement after discontinuation of medication overuse but should be given to patients if they have a primary headache plus ongoing medication overuse. The latter is defined as previously, i.e. 10 days or more of intake of triptans, ergot alkaloids mixed analgesics or opioids and 15 days or more of analgesics/NSAIDs or the combined use of more than one substance. If these new criteria for CM and MOH prove useful in future testing, the plan is to include them in a future revised version of ICHD-2.
